Arteriocyte is now a part of Isto Biologics.

News + Views


ISTO to Present at the 2015 Canaccord Genuity Musculoskeletal Conference on March 24, 2015

Mar 17, 2015

March 17, 2015 (St. Louis, MO) – ISTO Technologies, Inc., a privately-held orthobiologic regenerative medicine company, today announced that Phillip Kuhn, Chief Commercial Officer, will present at the 2015 Canaccord Genuity Musculoskeletal Conference as follows:

Date: Tuesday, March 24, 2015
Time: 11:00 a.m. PDT (2:00 p.m. EDT)
Location: MGM Grand, Las Vegas

About ISTO Technologies, Inc.
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. The Company’s proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue. In addition to cell-based cartilage products in clinical development, the Company has a commercial portfolio of orthobiologic products led by InQu®, a bone graft extender and substitute for spinal fusion applications that has been used in over 40,000 surgeries at U.S. hospitals to date. For additional information on ISTO, please visit our website at


To top